Literature DB >> 2543278

Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1.

M N Ellis1, R Waters, E L Hill, D C Lobe, D W Selleseth, D W Barry.   

Abstract

Infection of athymic mice with defined populations of acyclovir-susceptible (thymidine kinase [TK]-positive) and acyclovir-resistant (TK-deficient or TK-altered) herpes simplex virus type 1 strains was used to simulate herpetic skin disease of the immunocompromised host. In vitro characterization of the defined virus mixtures revealed that the dye uptake method was quite sensitive in the detection of small amounts (3 to 9%) of acylovir-resistant virus. Mice infected with homogeneous virus populations exhibited a good correlation between clinical response and the in vitro drug susceptibility of the infecting virus. Animals infected with defined mixtures of viruses exhibited varied patterns of infection and responses to acyclovir treatment. However, disease severity was useful in predicting the TK phenotype of virus recovered from lesions. Pathogenic, TK-altered virus was responsible for progressive disease in animals receiving low-dose (0.25-mg/ml) prophylactic acyclovir or high-dose (1.25-mg/ml) delayed therapy. Although this mutant was recovered infrequently, it was responsible for clinically significant disease in the animals from which it was isolated.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543278      PMCID: PMC171483          DOI: 10.1128/AAC.33.3.304

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Cellular immunity and herpesvirus infections in cardiac-transplant patients.

Authors:  K H Rand; L E Rasmussen; R B Pollard; A Arvin; T C Merigan
Journal:  N Engl J Med       Date:  1977-06-16       Impact factor: 91.245

Review 2.  Host determinants of response to antimicrobial agents.

Authors:  L Weinstein; A C Dalton
Journal:  N Engl J Med       Date:  1968-08-29       Impact factor: 91.245

3.  Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1.

Authors:  B A Larder; Y C Cheng; G Darby
Journal:  J Gen Virol       Date:  1983-03       Impact factor: 3.891

4.  Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir.

Authors:  J C Wade; C McLaren; J D Meyers
Journal:  J Infect Dis       Date:  1983-12       Impact factor: 5.226

5.  Thymidine plaque autoradiography of thymidine kinase-positive and thymidine kinase-negative herpesviruses.

Authors:  R B Tenser; J C Jones; S J Ressel; F A Fralish
Journal:  J Clin Microbiol       Date:  1983-01       Impact factor: 5.948

6.  Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child.

Authors:  C D Sibrack; L T Gutman; C M Wilfert; C McLaren; M H St Clair; P M Keller; D W Barry
Journal:  J Infect Dis       Date:  1982-11       Impact factor: 5.226

7.  Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase.

Authors:  B A Larder; D Derse; Y C Cheng; G Darby
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

8.  [125I]deoxycytidine used in a rapid, sensitive, and specific assay for herpes simplex virus type 1 thymidine kinase.

Authors:  W C Summers; W P Summers
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

9.  Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates.

Authors:  D S Parris; J E Harrington
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

10.  Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.

Authors:  H J Field
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

View more
  7 in total

Review 1.  Slipping and sliding: frameshift mutations in herpes simplex virus thymidine kinase and drug-resistance.

Authors:  Anthony Griffiths
Journal:  Drug Resist Updat       Date:  2011-09-22       Impact factor: 18.500

2.  Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates.

Authors:  Y F Yao; Y Inoue; T Kase; Y Uchihori; Y Mori; Y Ohashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

Review 3.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

4.  Synergistic therapy by acyclovir and A1110U for mice orofacially infected with herpes simplex viruses.

Authors:  M N Ellis; D C Lobe; T Spector
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

5.  Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.

Authors:  Jianmin Duan; Michel Liuzzi; William Paris; Francine Liard; Abigail Browne; Nathalie Dansereau; Bruno Simoneau; Anne-Marie Faucher; Michael G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

6.  High-frequency phenotypic reversion and pathogenicity of an acyclovir-resistant herpes simplex virus mutant.

Authors:  Anthony Griffiths; Donald M Coen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

7.  Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.

Authors:  J Duan; M Liuzzi; W Paris; M Lambert; C Lawetz; N Moss; J Jaramillo; J Gauthier; R Déziel; M G Cordingley
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.